Potassium Interactions

Spironolactone is a mineralocorticoid receptor antagonist that blocks aldosterone-driven potassium excretion in the collecting duct, causing the kidneys to retain potassium. Adding a potassium supplement, salt substitute, or potassium-rich diet on top of spironolactone can produce fatal hyperkalemia, especially in patients with chronic kidney disease, heart failure, diabetes, or who are also on an ACE inhibitor or ARB.

Lisinopril blocks the renin-angiotensin-aldosterone system, reducing aldosterone secretion and impairing the kidneys' ability to excrete potassium. Adding potassium supplements on top of this can push serum potassium into dangerous territory, especially in older adults or those with reduced kidney function.

Losartan blocks the angiotensin II receptor, lowering aldosterone and reducing renal potassium excretion in the same way ACE inhibitors do. Concurrent potassium supplementation can drive serum potassium into the hyperkalemic range, with cardiac arrhythmia risk in patients with kidney impairment, diabetes, or heart failure.

Furosemide blocks the Na-K-2Cl cotransporter in the loop of Henle and is the most potent diuretic class for causing dose-dependent hypokalemia, affecting 25-36% of users. Supplementation or potassium-sparing co-therapy is frequently required, but uncontrolled dosing combined with ACE inhibitors or kidney disease can flip levels into hyperkalemia.

Valsartan is an angiotensin II receptor blocker that suppresses aldosterone and slows renal potassium excretion. The FDA-approved Diovan label specifically warns that potassium supplements and potassium-containing salt substitutes may lead to clinically significant hyperkalemia, particularly in patients with renal impairment, diabetes, or heart failure.

Hydrochlorothiazide promotes urinary potassium excretion at the distal convoluted tubule and is a leading cause of drug-induced hypokalemia. Many patients still develop low potassium despite supplementation, while some on combination antihypertensives risk the opposite problem if a potassium-sparing agent is added.

Prednisone has weak mineralocorticoid activity that promotes renal potassium excretion. Especially at higher doses or with prolonged use, this can cause hypokalemia, which presents as muscle weakness, fatigue, and potentially arrhythmias.

Magnesium is required for the Na/K-ATPase pump that maintains intracellular potassium, so magnesium deficiency causes refractory potassium loss that cannot be corrected by potassium alone. Co-supplementation of the two minerals produces additive reductions in systolic blood pressure and supports normal cardiac rhythm.